Introduction
Estrogens are well known to have critical roles in development and progression of breast cancer (1) . Notably, the majority of breast cancers express the estrogen receptor alpha (ERa), a member of the steroid/ nuclear receptor superfamily of ligand-inducible transcription factors and thus respond to the mitogenic actions of estrogen (2) . Upon binding to estradiol, ERa undergoes a major conformational change, recruits a multitude of coactivator and corepressor molecules to cognate DNAresponse elements located at the promoter/enhancer elements of target genes, to initiate or inhibit the transcription of genes that regulate the growth of breast cancer cells (3) . Most early-stage mammary tumors are ERa positive (4) and pharmacotherapy of these cases relies heavily on the ability to block the activity of ERa, using specific antagonists or selective downregulators (5) . Thus, selective ERa antagonists, such as tamoxifen, are used extensively for treating early-stage breast cancer and have great therapeutic relevance (6) .
Besides endogenous estrogens, numerous compounds of botanical origin can exert estrogenic effects in vitro and in vivo. Despite their estrogenicity, consumption of phytoestrogens has been paradoxically associated with reduced risk of breast cancer (7) (8) (9) . There is intriguing data that different classes of phytoestrogens can exert differential effects on the growth and development of estrogen-driven breast cancer in animal models. The intestinal phytoestrogen enterolactone inhibited the growth of estrogen-stimulated breast cancer xenografts, whereas the soy flavonoid genistein did not display this suppressive effect (10) . Interactions between ER-active compounds may also be dose dependent, as low doses of genistein promoted the development of breast cancer in tamoxifen-treated wild-type erbB-2/neu transgenic mice, whereas higher doses of genistein prolonged tumor latency (11) . Among phytoestrogens, prenylflavone compounds originally isolated from beer are among the most ER active compounds (12, 13) . Prenylflavones are ubiquitous in fruits and vegetables, such as hops, apple, strawberry, persimmon, grape, onion and cucumber (14) . In particular, plants of the genus Epimedium (Berberidaceae) are rich in prenylflavones and their extracts are traditionally used in East Asian countries to improve bone health (15, 16) and other menopausal symptoms. The main prenylflavone in Epimedium is icariin whose active metabolite is icaritin ( Figure 1A ). Icaritin has been reported to have antitumor activity in several in vitro studies performed on hepatoma (17) , gastric (18) , prostate (19) and endometrial (20) cancer cells. Nevertheless, the effects of icaritin on breast cancer cell growth are uncertain. Although icaritin exert estrogenic effects, the prenylflavone has been reported to inhibit (21) or enhance (22) the growth of breast cancer cells. The ultimate effects of icaritin on breast cancer cell growth remain unresolved.
To investigate the hypothesis that icaritin may have significant antiproliferative properties, we studied its effects on breast cancer cell growth and gene expression, alone and when co-administered with estradiol. Counterintuitively we found that although icaritin and estradiol individually increased breast cancer cell proliferation, their joint effect was suppressive compared with the effect of either alone. Investigations indicated a unique mechanism whereby the estradiol and icaritin act jointly to profoundly degrade ERa protein through aryl hydrocarbon receptor (AhR)-mediated pathways leading to suppression of estradiol-stimulated breast cancer cell growth in vitro and in vivo. Thus, icaritin was a dual agonist that could exert estrogenic effects but which restricted excessive estrogenic stimulation through its ability to destabilize ERa protein.
Materials and methods

Cell cultures
Cell lines were obtained from American Type Culture Collection. All cell lines were grown in a 37°C incubator with 5% CO 2.
Chemicals Icaritin (purity .98%) was provided by Dr Wilmar, Schwabe Pharmaceuticals (Karlsruhe, Germany). Dimethylsulfoxide (DMSO), estradiol, 4-hydroxytamoxifen, 3-methylcholanthrene, genistein and MG-132 were purchased from Sigma (Sigma-Aldrich). [ culture media containing test sample(s) at desired concentrations in DMSO. The cells were incubated with treatment media for 6 days with media renewal at 48 h intervals. MDA-MB-231 cells were treated under identical conditions as MCF-7 cells to serve as controls. All experiments were performed in four replicates. Cell proliferation was determined using Cyquant TM Cell Proliferation Assay (Invitrogen) and CellTiter 96Ò Aqueous Non-Radioactive Cell Proliferation Assay (MTS) (Promega) or counted under an inverted microscope with a hemocytometer. For cell counting, the cells were trypsinized with 100 ll trypsin and 10 ll of the cell suspension was counted on a hemocytometer. Cell proliferations were expressed as fold increase over DMSO-treated cells.
Luciferase reporter assay pERE-luciferase reporter assay. Stably transfected HeLa-ERE4-Luc cells (23) were treated with the chemicals for 24 h, lysed and the luminescence was measured with Luciferase Assay System (Promega) in a GloMax TM 20/20 Luminometer (Promega). Transcriptional activity was expressed relative to that obtained with 1 nM estradiol (100%) and values were presented as mean ± standard error of the mean of triplicates.
pXRE-luciferase reporter assay. MCF-7 cells were transfected with pXRE2-luc containing two consensus copies of the xenobiotic response element using AmaxaÒ Cell Line NucleofectorÒ Kit V (Amaxa Inc.). At 24 h post transfection, cells were incubated with treatment media for 24 h and the luminescence measured. The results were representative of at least three independent experiments.
Western immunoblotting MCF-7 cells were seeded in 24-well plates at density of 1 Â 10 5 cells per well. The cells were treated with ligands for 24 h. Whole-cell extracts were harvested using MPER Mammalian Protein Extraction Reagent (Thermo Scientific) and protein concentration determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA). Proteins (10 lg/sample) was resolved on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and transferred to nitrocellulose membrane using iBLOT (Invitrogen). Blots were probed with anti-ERa antibody and AhR antibodies (Santa Cruz Biotechnology). Anti-b-actin antibody (SigmaAldrich) was used as loading control. Densitometry analysis was performed by quantifying the band intensities on the immunoblot using ImageJ (National Institutes of Health).
Knockdown analysis using siRNAs Validated small interfering RNA (siRNA) directed against a control nontargeting sequence (siScrambled) or AhR (siAhR) were obtained from Qiagen. MCF-7 cells were transfected with siRNA using AmaxaÒ Cell Line NucleofectorÒ Kit V following manufacturer's instructions. Cells were plated in 12-well plates at density of 2 Â 10 5 cells per well after transfection. After 24 h, the cells were incubated with ligands for indicated time points. The knockdown efficiency was verified by real-time PCR quantification of AhR messenger RNA (mRNA) levels or western blotting for protein expression. AhR competitive ligand-binding assay Male C57BL/6 mice (20 g) were purchased from Charles River Laboratories (Wilmington, NC) and maintained in a 12 h light: 12 h dark cycle with free access to food and water. Hepatic cytosol was prepared in HEDG buffer [25 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid, pH 7.5, 1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol and 10% (vol/vol) glycerol] as described previously (24) . Aliquots of mouse hepatic cytosol (2 mg/ml) were incubated with 2 nM [ RNA isolation and reverse transcription-PCR MCF-7 cells were seeded in 24-well plates at density of 1 Â 10 5 cells per well. The cells were incubated with ligands for 6 or 24 h. Total RNA was extracted from cultured cells using RNeasy mini kits (Qiagen). First strand complementary DNA (cDNA) was synthesized from 500 ng of total RNA using SuperScript TM III Reverse Transcriptase (Invitrogen).
ERa ligand binding assay
Quantitative real-time PCR
The synthesized cDNA was diluted to 1:100, 9 ll of the diluted mixture was used. Quantitative real-time PCR was performed using Taqman Gene Expression Assay and Taqman Fast Universal PCR Mix using StepOnePlus RealTime PCR System (Applied Biosystems). The expression levels of GREB1, 
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CYP1A1 and AhR were normalized to that of 18S ribosomal RNA. The results were representative of at least three independent experiments.
Microarray experiment MCF-7 cells were first grown in phenol red-free Eagle's minimum essential medium containing 10% charcoal-treated fetal bovine serum in a monolayer culture for a week, with medium change performed on every alternate day. After 7 days, the cells were trypsinized and seeded onto 12-well plates at a density of 1 Â 10 3 cells per well. Cells were incubated with test compounds dissolved in phenol red-free cell culture medium containing 5% dextran-coated charcoalstripped fetal bovine serum for 6 h. Total RNA was extracted using the RNeasy Mini Kit as described by the manufacturer. Total RNA was amplified to yield biotinylated cDNA and then purified using the Illumina RNA amplification kit (Ambion Inc.). Seven hundred and fifty nanograms of amplified biotinylated cDNA were used. Gene expression analysis was executed using Illumina Sentrix HumanRef-8 V2 BeadChip Arrays containing $23 000 transcripts. Fluorescence detection was carried out by confocal laser scanning with the Illumina BeadArray Reader at 532 nm and 0.8 lm resolution.
Analysis of global gene expression
GeneSifter software (Geospiza) was used to identify differential gene expression due to ER-dependent regulation. Microarray data from triplicate experiments were subjected to analysis of variance. ER-regulated genes were defined to be those that were changed by !2-fold and statistically different from control cells treated with vehicle where the adjusted P value using the Benjamini and Hochberg procedure (BH-adjusted P value) is ,0.0001.
Xenograft models
Athymic and ovariectomized female nude mice (Balb/c nu/nu), 5-to 6-weekold, were obtained from Harlan (Harlan). After 1 week of acclimatization, an estradiol pellet (0.72 mg, 90 day release, inducing 3-4 nM estradiol in blood, Innovative Research of America) was implanted subcutaneously under the neck using a trochar. After 1 week, an MCF-7 cell suspension containing 2 Â 10 6 cells in Matrigel (BD Biosciences) was subcutaneously injected into the two mammary fat pads of each animal. The tumor volume was calculated using the formula (length/2) Â (width/2) Â (width/2) Â p. Four weeks after estradiol implantation, when tumor volume reached 100 mm 3 , the mice were randomly divided into four groups such that the tumor size and body weight were similar within each group (eight mice per group). Estradiol pellets were removed from Groups 1 and 2. Group 1 (placebo) was fed with soy-free mouse feed (Altromin, Germany). Group 2 (icaritin) was fed with soy-free mouse feed and injected intraperitoneally with 10 lmol/kg icaritin every 2 days. Groups 3 (estradiol pellet) and 4 (icaritin þ estradiol pellet) were treated in the same way as Groups 1 and 2, except estradiol pellets were not removed. Tumor volume and body weight were monitored weekly. Mice were killed after 9 weeks of treatment. Tumors were excised, weighed and processed for western blot analysis. Ethical approval for the study was granted by the Institutional Animal Care and Use Committee, Biological Resource Center, Singapore.
Statistical analyses
Mixed effects linear regression was performed to determine the relationship between treatment and the rate of tumor growth over time. The tumor volume determined in the animal studies was log-transformed and used as the dependent variable. The best-fit coefficient [and confidence interval (CI)] derived was used to calculate average tumor growth per week in each treatment group, and the difference between the estradiol þ icaritin and estradiol alone groups was compared. Analyses were performed using Stata version 10.1 (College Station, TX) using the xtmixed command. Values were expressed as mean ± standard error of the mean. Statistical differences among treatment and control groups were evaluated by analysis of variance followed by Bonferroni test for multiple comparisons, using SPSS Ò (SPSS Inc.). P , 0.05 was considered significant.
Results
Differential effects of icaritin and estradiol/icaritin on cell proliferation Breast cancer cells (MCF-7) were exposed to estradiol and icaritin, alone and in combination for 6 days, and their effects on cell growth were measured. Icaritin alone stimulated MCF-7 cell proliferation reaching maximal growth at 5 lM, followed by a decline at 10 lM ( Figure 1B ). Maximal proliferative effects of icaritin were comparable with those observed with estradiol but with potency that was several orders of magnitude lower. In comparison, 4-hydroxytamoxifen, the active metabolite of tamoxifen, did not increase MCF-7 proliferation.
To explore the effects of icaritin in combination with estradiol, MCF-7 cells were exposed to increasing concentrations of icaritin in the presence of a high concentration of estradiol (100 pM) ( Figure 1C ). In contrast to the stimulatory effects of estradiol or icaritin alone, the presence of icaritin at concentrations !1 lM suppressed estradiol-stimulated cell growth, measured using two different methods ( Figure 1C and D). When cells were exposed to 1 lM icaritin and varying concentrations of estradiol, estradiol even at large concentrations was unable to restore cell growth ( Figure 1E ). Maximal cell proliferation with the icaritin/estradiol combination was also about one-third lower than that observed with estradiol alone ( Figure 1E ). Repeated experiments indicated that combination of icaritin at its EC 50 or C max concentration with 100 pM estradiol can reduce the breast cancer cell growth by 21 and 42%, respectively, compared with the effects observed with estradiol alone (Supplementary Figure 1 is available at Carcinogenesis Online). Suppressive effects of icaritin on estradiol-stimulated growth was also confirmed by direct cell counting, with icaritin þ estradiol treatment resulting in 37.5% lower cell counts compared with either ligand alone ( Figure 1F ).
Differential effects of icaritin and estradiol/icaritin on ER-dependent gene expression
To investigate whether inhibition of growth was associated with changes in estrogen-regulated gene expression, we measured the effects of the icaritin/estradiol combination on expression of GREB1, a critical hormone-dependent regulator of breast cancer growth (25, 26) . As expected, the presence of 4-hydroxytamoxifen reduced GREB1 mRNA levels ( Figure 2A) . After 6 h of treatment with estradiol, a concentration-dependent increase in GREB1 mRNA level was observed with icaritin treatment (0.01-1 lM). Remarkably, the combination of estradiol/icaritin resulted in a significant reduction in GREB1 mRNA compared with the individual effects of estradiol and icaritin, 65 and 52%, respectively ( Figure 2B ). This suppressive effect was lower than that observed for the 4-hydroxytamoxifen/estradiol combination. At 24 h, the suppressive effect was even more pronounced, with GREB1 mRNA levels being 97 and 89% lower ( Figure 2C ) than E 2 or icaritin treatment alone, respectively. Reduced GREB1 expression in the presence of icaritin/estradiol mimicked their suppressive effects on breast cancer cell proliferation as shown in Figure 1B- Figure 2D ). In HeLa cells stably transfected with ERa and estrogendriven reporter genes, estradiol or icaritin alone increased estrogenregulated promoter activity ( Figure 2E ). However, the joint effect of estradiol and icaritin on transcription was unexpected, in that the presence of icaritin (1 lM) suppressed estrogen-stimulated transcriptional activity by about a third and this effect could not be reversed by high concentrations of estradiol ( Figure 2F ). Unexpected modulatory effect on estrogen-stimulated ERa promoter activity of the icaritin/estradiol combination was not due to changes in cell number (data not shown).
Icaritin binds AhR to regulate AhR-mediated transcriptional activity and cell proliferation To identify the mechanism(s) that mediate suppressive effects of icaritin on estradiol-stimulated signaling pathways, we performed gene expression microarray analyses in breast cancer cells exposed to these ligands. The heat map generated using stringent criteria (adjusted P , 0.0001) suggested that icaritin induced a pattern of gene expression that was dissimilar with respect to estradiol, genistein and 4-hydroxytamoxifen (Figure 3 ). In particular, hierarchical clustering placed CYP1A1 in an isolated node, indicating that the expression of CYP1A1 was significantly different from other genes in this panel. Treatment with icaritin increased CYP1A1 mRNA level by 5.5-fold compared with estradiol (Supplementary Table 1 is available at Carcinogenesis Online). Interestingly, CYP1A1 is a key enzyme in xenobiotic metabolism and its expression is activated by the AhR in a ligand-dependent manner through its ability to bind xenobiotic response elements (XREs) in its promoter (24) . To investigate the relationship of icaritin and AhR signaling, we performed quantitative reverse transcription-PCR on CYP1A1 mRNA using 3-methylcholanthrene, a known AhR agonist, as a positive control (27) . As expected, 3-methylcholanthrene increased CYP1A1 mRNA level by more than 10-fold ( Figure 4A) . Consistent with the microarray data, icaritin, but not estradiol or 4-hydroxytamoxifen, increased CYP1A1 expression in a concentration-dependent manner. To determine whether icaritin is a cognate ligand for AhR, the ability of ligand to competitively reduce the specific binding of the potent AhR agonist To investigate the effects of icaritin-activated AhR activity on breast cancer cell growth, we performed experiments whereby AhR was silenced using RNA interference. Transfection of siAhR reduced the expression of AhR mRNA by $85% at 24-48 h time points compared with cells expressing a scrambled siRNA sequence (Supplementary Figure 3 is available at Carcinogenesis Online). As expected, icaritin After 6 h, cells were harvested using RNeasy Mini Kit. Biotinylated cDNA was generated and hybridized on to Illumina Sentrix BeadChip. The heat map generated suggested that icaritin induced a pattern of gene expression that was dissimilar with respect to estradiol, genistein and 4-hydroxytamoxifen. GeneSifter software was used to identify differential gene expression. Microarray data from triplicate experiments were subjected to analysis of variance. A differentially regulated gene was defined as one that was activated or inhibited !2-fold and statistically different from the control cells treated with vehicle. Adjusted P value ,0.0001. Refer to Supplementary Table 1, available at Carcinogenesis Online for list of genes that are differentially expressed.
Ã CYP1A1 signal was induced by icaritin but not other ligands.
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suppressed estradiol-stimulated growth in cells expressing scrambled siRNA ( Figure 4C ). While siRNA suppression of AhR restored the growth of estradiol-stimulated breast cancer cells, it blocked the suppressive effect of high concentrations of icaritin alone on cell growth ( Figure 4D ), an effect not observed with estradiol ( Figure 4E ). Silencing of AhR also resulted in reversal of the icaritin-dependent inhibition of estradiol-stimulated GREB1 mRNA expression ( Figure 4F ). Overall, our data indicated that suppressive effect of high concentrations of icaritin on estradiol-stimulated cell growth and gene expression may be mediated, at least partially, through AhR signaling pathways.
Estradiol/icaritin destabilized ERa protein through AhR-mediated proteasome pathways
While the AhR has been shown to repress estrogen-and ER-dependent signaling by multiple mechanisms (28), a major mechanism is the ability of the AhR to promote proteolysis of ERa through assembly of an ERa-specific ubiquitin ligase complex (29, 30) . To explore the hypothesis that suppressive effects of icaritin on estradiol-stimulated cell proliferation may be related to AhR-directed proteolysis of ERa, we examined the effect of icaritin on ERa protein stability using immunoblotting. In breast cancer cells, icaritin dose-dependently destabilized ERa protein ( Figure 5A ). Unlike 4-hydroxytamoxifen that stabilized ERa protein, icaritin and estradiol independently reduced ERa protein levels ( Figure 5B ). However, the most striking effect on ERa stability was observed with the estradiol/icaritin combination. The presence of icaritin/estradiol in combination resulted in 83 and 68% lower ERa protein levels compared with the individual effects of estradiol and icaritin, respectively (P , 0.001) ( Figure 5B ).
Destabilization of ERa in the presence of icaritin and estradiol was partially reversed by addition of proteasome inhibitor MG132, suggesting that these changes were partially mediated through the proteasomal pathway. These effects could not be attributed to changes in ERa mRNA levels (Supplementary Figure 4 is available at Carcinogenesis Online). The additional effect of icaritin on ERa stability in the presence of estradiol was dose dependent ( Figure 5C ), consistent with its suppressive effects on the estradiol-stimulated growth of these breast cancer cells.
To test the role of the AhR in ERa stability, we performed experiments whereby AhR was silenced using RNA interference. MCF-7 cells were transfected with siAhR and treated with icaritin and estradiol. Knockdown of AhR gene induced a partial rebound in ERa protein ( Figure 5D ), congruent with the observation that AhR mediates this action of icaritin. In contrast, knockdown of AhR gene did not restore estradiol-mediated degradation of ERa. Most strikingly, destabilization of ERa protein by icaritin/estradiol was blocked by AhR knockdown ( Figure 5D ).
Estradiol/icaritin reduced ERa content to inhibit mammary tumor growth in a xenograft model
To evaluate the role of estradiol, icaritin and icaritin/estradiol combination on tumor proliferation in vivo, we examined the effects of these treatments on the growth of MCF-7-derived breast tumors in a xenograft mouse model. Growth of tumors in mice injected with icaritin, with or without estradiol implanted, was compared with animals fed a soy-free placebo diet. Animals fed placebo or injected with icaritin alone did not show any growth of xenografts ( Figure 6A, upper panel) . Ã , P , 0.05, n 5 3.
Icaritin restricts breast cancer cell growth
As expected, tumor xenografts exposed to estradiol grew at a rate of 19.4% (95% CI 16.8-22.1%) per week. In comparison, the increase in tumor size in the estradiol þ icaritin group was significantly lower at 11.3% per week (95% CI 8.6-14.1%) ( Figure 6A , lower panel). Using the mixed-effect model, reduction in growth with estradiol þ icaritin versus estradiol alone was 6.8% (95% CI 3.6-9.8%) (P , 0.001). The excised tumors from the icaritin þ estradiol group in week 9 had an average size of 402.9 mm 3 , whereas average tumor size from estradiol group was 478.4 mm 3 . There was no apparent change in body weight in animals in each group (data not shown). Xenograft tumors were processed for immunoblot analysis to study the effect of icaritin in ERa stability in vivo. As expected, ERa protein levels were high in tumors from placebo-fed animals, comparable wtih that observed in MCF-7 cells cultured in vitro ( Figure 6B , last lane). Either estradiol or icaritin alone reduced ERa protein levels in tumors, consistent with their in vitro effects observed earlier in Figure 5 . Strikingly, the estradiol/icaritin in combination was associated with a nearly complete destabilization of ERa protein, such that ERa protein was almost undetectable ( Figure 6B , lane 4), indicating that slower xenograft breast cancer growth in the presence of estradiol/icaritin likely resulted from ERa degradation.
Discussion
In this study, we described an unexpected mechanism whereby the prenylflavone icaritin restricted estradiol-stimulated breast cancer cell growth by activating AhR signaling. Complementing estradiol-mediated degradation pathways, activation of AhR resulted in a profound destabilization of ERa protein, removing a critical driver for the proliferation of breast cancer cells. Icaritin was an estrogenic ligand that stimulated ER-regulated gene expression and could induce the growth of breast cancer cells on its own. However, the effects of icaritin in combination with estradiol were unexpected. The estradiol/icaritin combination induced cell proliferation that was lower than that observed with either icaritin or estradiol alone. Although icaritin and estradiol individually stimulated expression of the ERa-regulated gene GREB1, the estradiol/ icaritin combination unexpectedly suppressed GREB1 mRNA expression and was associated with reduced ERE-regulated reporter gene activity. This suggests a role for an additional pathway(s) in mediating the action of icaritin. In microarray studies, CYP1A1 was identified, using stringent criteria, as the gene whose expression was most differentially induced by icaritin. Since CYP1A1 is mainly regulated by AhR/ aryl hydrocarbon receptor nuclear translocator acting through multiple consensus XRE sequences in its promoter (31), we deduced that the suppressive effects of icaritin on estradiol-stimulated growth might be mediated through AhR signaling. Our data indicate that icaritin was an AhR agonist. Icaritin competitively reduced specific binding of the potent AhR agonist TCDD, stimulated XRE-reporter gene activity and increased CYP1A1 mRNA levels. Recently, liganded AhR has been reported to be an ERa-specific E3 ligase, promoting proteasomal degradation of ERa through targeted assembly of the ubiquitin ligase complex, CUL4-BAhR (32). 
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Since icaritin was able to activate AhR signaling, we examined the hypothesis that ERa protein could be degraded through AhRmediated proteasomal pathways. Indeed, icaritin could destabilize ERa protein in a concentration-dependent manner. The almost complete degradation of ERa by high concentrations of icaritin provides one possible rationale for the biphasic action of icaritin ( Figure 1B and C) on breast cancer cell proliferation, a phenomenon which has also been observed in other laboratories (21) . At low concentrations, icaritin being estrogenic was pro-growth. However, higher concentrations of icaritin activated AhR and destabilized ERa protein ( Figure 5A ), resulting in suppression of cell growth, an effect which can be reversed by silencing AhR ( Figure 4D ). Intriguingly, destabilization of ERa by the estradiol/icaritin combination was greater than that observed for either compound alone. ERa protein stability was partially restored when AhR was knocked down by siRNA. While reduction of AhR abolished the restrictive effect of icaritin on estradiol-dependent breast cancer cell growth and gene expression, transfection with siAhR did not reduce estradiol-induced cell proliferation or gene expression. In an athymic nude mouse model, icaritin restricted estradiol-stimulated mammary tumor xenograft growth. It is noteworthy to mention that based on our previous studies, icaritin can be detected at concentrations ranging between 0.5 and 3 lM in the sera of animal models after oral ingestion of the Epimedium standard extract despite constituting only 10% of the total Epimedium standard extract (16, 33) . Therefore, the concentrations of icaritin used in this study are physiologically achievable and sufficient to bind ERa and AhR as shown in Figures 2D and 4B , respectively, to exert pharmaceutical action against breast cancer. Overall, our data support the concept that icaritin, through AhR-directed proteasomal degradation, leads to profound degradation of ERa protein thereby restricting estradiol-stimulated breast cancer cell growth and gene expression.
Our study suggests the critical role of ERa stability in the regulation of breast cancer cell proliferation. In common with many shortlived transcription factors that affect cell proliferation, ERa expression is tightly linked to its degradation. Basal ERa ubiquitination and proteasomal degradation are achieved through interaction with Hsc70-interacting protein acting as an E3-ubiquitin ligase (34) . In the presence of estradiol, ERa degradation is accelerated, reducing the halflife of ERa protein from 5 days to 3-4 hours (35). Estradiol-mediated turnover of ERa has been linked with activation of extracellular signalregulated kinase (ERK) 7, the loss of which is associated with breast cancer progression (36) . There is also evidence that estradiol-ERa attracts sequentially the coactivator SRC3 and then the 20S proteasome subunit LMP2 (37, 38) leading to ubiquitination and 26S proteasome degradation. Our data suggest another distinct pathway whereby an estrogenic ligand can affect ERa stability. In this model, icaritin was also an AhR agonist inducing AhR-mediated mechanisms to target ERa protein for accelerated proteasome degradation.
AhR is expressed in tissues from normal and cancerous breasts (39) and its detoxification functions through induction of the metabolizing enzyme CYP1A1 are widely known (40) . Although evolutionary and structurally dissimilar to the steroid hormone receptor family, AhR is the only known ligand-activated member of the basic helix-loop-helix/ PAS family of transcription factors. There is increasing evidence that AhR signaling intersects with ER function and a variety of AhR-ER cross talk mechanisms have been proposed including targeting of ER for degradation, inhibitory ERE elements, squelching mechanisms, ER:AhR and ER:aryl hydrocarbon receptor nuclear translocator interactions (28) . Moreover, targeted disruption of AhR in the mouse results in altered ovarian follicle and mammary development (40, 41) . Recent studies of an in vitro model of human breast cancer indicate that ligandactivated AhR can inhibit cellular motility and can promote expression of markers for cell differentiation, and knockdown of AhR reversed this effect (39) . The AhR ligand dioxin is able to reverse the proliferative effects of estrogens in vitro and in vivo (42) . Although antiproliferative effects of AhR may be mediated through non-estrogen-dependent pathways by stimulating p27kip1 expression and interfering with E2F-RB (43, 44) , our study indicates that its ability to degrade ERa protein may be critical. This concept is reminiscent of the finding that AhR, activated by natural ligands in the diet, increases b-catenin degradation to reduce intestinal cancer in the APC mutant mice (45) . Further studies are required to determine if consumption of dietary flavonoids that activate AhR may ultimately reduce the risk of estradiol-stimulated breast cancer.
Interestingly, it has also been reported that the combination of estradiol and the AhR agonist TCDD reduced ERa protein more than either estradiol or TCDD alone (28) . Administration of TCDD can result in suppression of estradiol-dependent growth of xenotransplanted human Fig. 6 . Effect of icaritin treatment on human breast cancer cell xenografts. Mice bearing breast cancer (MCF-7) xenografts were fed soy-free feed and randomized to placebo, estradiol (E2) pellet implantation, icaritin (ICT) injected intraperitoneally or receiving both estradiol pellets and ICT injections (E2 þ ICT). (A) Tumor volume was measured weekly until mice were killed at week 9. Mixed effects linear regression was performed to determine the relationship between treatment and the rate of tumor growth over time (lower panel).
Ã ICT treatment inhibited E2-induced tumor xenograft growth rate (P , 0.001). (B) Effect of treatments on ERa protein levels. Tumors were excised and protein extracted. Immunoblot analyses were performed on 20 lg of protein extracts from each treatment group. The intensity of ERa signal was measured, normalized to ß-actin and compared with ERa-positive (MCF-7) and -negative (MDA-MB-231) cell extracts. ICT plus E2 induced greater ERa degradation compared with E2 and ICT alone. Results are the means ± standard error of the mean, Ã , P , 0.05, n 5 4. Representative western blot is shown.
Icaritin restricts breast cancer cell growth MCF-7 breast cancer (46) . However, polyhalogenated hydrocarbons such as TCDD and other dioxins are unsuitable as anticancer agents because of their inherent carcinogenic properties (47) , although less toxic forms are being examined for such purposes (28) . However, it has to be noted that icaritin may inhibit estrogen-responsive breast cancer cell growth through non-genomic mechanisms. Such non-nuclear membrane-initiated mechanisms have been reported to underlie the proapoptotic effect of estrogens in bone cells (48) . A membrane-associated splice variant of ERa (ERa-36) can exert sustained activation of mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) to cause apoptosis in osteoclasts (49) . The MAPK/ ERK mechanisms may even be independent of ERa signaling since icaritin at high doses have been reported to activate MAPK/ERK signaling pathways to cause cell cycle arrest and to inhibit the growth of ERa-negative breast cancer cells (21) . Whether icaritin can activate ERa-36 and/or MAPK/ERK signaling to regulate breast cancer cell proliferation will require future studies. This study presents the novel concept that estrogenic prenylflavones like icaritin may activate AhR signaling to enhance proteasomal degradation of ERa, thus reducing maximal estrogen responsiveness. When icaritin was co-administered with estradiol, the net effect was counterintuitive, in that icaritin/estradiol combination was unable to induce maximal breast cancer cell proliferation due to destabilization of ERa. Our studies predict that the consequence of icaritin administration or its glycosylated precursors to women may not stimulate breast cancer growth but may in fact be suppressive in the presence of endogenous estradiol. Being a dual agonist for both ER and AhR signaling, icaritin may serve as a framework for the development of compounds for estrogen replacement therapy but with reduced risk of undesirable adverse effects due to excessive estrogenic stimulation. Given the current challenges in treating aggressive metastatic breast cancer, the clinical development of compounds with enhanced selective AhR activity might provide an effective adjuvant therapy for ERa-positive breast cancers.
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Supplementary Figures 1-4 and Table 1 can be found at http://carcin. oxfordjournals.org/. 
